bristol myers squibb co medical journal spurs fda review of antibiotic the food and drug administration said it is conducting a safety review of maxipime a bristol myers squibb co antibiotic after a study in a medical journal suggested the drug might be linked to an increased risk of death the fda said the review will take four months and it isnt recommending any prescribing changes other than telling health care professionals that they should consider the risks and benefits of the drug also known generically as cefepime maxipime is marketed in the u s by elan corp plc maxipime is an injectable antibiotic approved for use in treating serious infections like pneumonia 
